Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp is a clinical-stage biotechnology company with operations in Israel. It is developing RNA interference (RNAi) therapies for cancers driven by KRAS mutations.

Its first product candidate, LODER, delivers a small interfering RNA that targets mutated KRAS through a miniature biodegradable implant placed directly into the tumor. LODER has been studied together with chemotherapy in patients with locally advanced pancreatic cancer. The company is also developing next-generation siRNA candidates designed for systemic delivery, which could reach additional KRAS-driven tumor types.

Silexion became a public company by merging with a special purpose acquisition company. Its ordinary shares trade on the Nasdaq under the ticker SLXN.